1'756 companies found
Apofilm SA
Morges · Since 1988
Apolab SA
Peseux · Since 2024
The core activity of Apolab is the manufacture of high-quality preparations, in particular magistral formulas and formula officinalis, ranging from simple to complex preparations, including medications, cosmetics and dietary supplements. The company produces sterile and non-sterile preparations in small quantities and also offers individually tailored preparations upon request.
Apotheke Roter Ochsen AG
Glarus · Since 2019
The core activity of Formula Labor is the manufacture of special recipes and medicines, in particular pharmaceuticals that are no longer available on the market. This includes both sterile and non-sterile productions, as well as analytics and the creation of study samples. The company offers contract manufacturing services for pharmacies, medical practices and clinics, and has a wide range of active and auxiliary substances in GMP-tested pharmaceutical quality.
Apricot Therapeutics AG
Zurich · Since 2022
The core activity of Apricot BIO is the development and application of Drug Response Profiling for Systems Medicine, particularly in the field of cancer treatment. This involves researching and analyzing the deep molecular phenotyping of individual cells in response to anti-cancer drugs, enabling personalized treatment recommendations.
APTISSEN SA
Plan-Les-Ouates · Since 2013
Aptissen develops and distributes medical products, particularly orthobiological solutions for the treatment of muscle and joint pain. The company's core activities include research, development and marketing of products such as Synolis VA and Cartylis, which are used for tissue regeneration and repair.
Arakena Pharmaceuticals AG
Basel · Since 2024
Arakena Pharmaceuticals AG focuses on discovering and developing GRK5 inhibitors as a first‑in‑class treatment for acute and chronic cardiomyopathies, including Takotsubo cardiomyopathy. The company in‑licenses mid‑stage discovery compounds and develops drug‑like, GRK‑selective inhibitors, applying AI‑assisted decision tools and university‑licensed intellectual property to advance preclinical and clinical development.
Arela AG
Schaffhausen · Since 2010
The core activity of ARELA is to offer pharmaceutical products and services from selected partners in Asia, Europe and Latin America, particularly in the fields of ophthalmology and oncology. ARELA acts as a reliable partner and gateway for these products and services in selected markets, such as Korea, Japan, Europe and Latin America.
argento com GmbH
Kreuzlingen · Since 2007
The core activity of Argento com is the development, manufacture and marketing of medical products, dietary supplements and pharmaceuticals, as well as the provision of health services. The company focuses on improving the health and quality of life of people.
argenx Switzerland SA
Châtelaine · Since 2020
argenx Switzerland SA is a biopharmaceutical company that discovers, develops and commercializes antibody-based therapies for severe autoimmune diseases. Its portfolio includes the FcRn-targeting agent efgartigimod (marketed as VYVGART and VYVGART Hytrulo), a pipeline of additional antibody candidates such as empasiprubart, and ongoing clinical research.
Asceneuron SA
Eysins · Since 2012
The core activity of Asceneuron SA is the development of innovative small molecules and Tau modifiers for the treatment of diseases, particularly in the area of the central nervous system (CNS). The company focuses on the early stages of drug development and conducts clinical trials to test the efficacy and safety of its active ingredients.
Aschem GmbH
Allschwil · Since 2018
The core activity of ASCHEM GmbH is the development, synthesis and marketing of various chemical building blocks for drug development and production, as well as the provision of services in the field of nanotechnology, including the development of nano-based drug formulations and targeted drug delivery systems.
ASSOCIAZIONE ALAN GHITIS per la Lotta contro il Cancro
Paradiso · Since 2019
The company's core activity is the development of personalized oncological treatments through the application of artificial intelligence, machine learning and structure-based drug design, with the goal of developing effective therapies for cancer patients.
Astellas Pharma AG
Wallisellen · Since 1987
The core activity of Astellas Pharma AG is the development, manufacture and marketing of pharmaceuticals, particularly in the therapeutic areas of oncology, urology, nephrology and transplantation. The company is also engaged in research and development of new medicines and supports medical training and clinical studies.
ASTRA Therapeutics AG
Villigen · Since 2019
The core activity of ASTRA Therapeutics is the development of precision-crafted medicines to combat eukaryotic pathogens, particularly protozoa that cause infections in humans, animals and plants. The company focuses on developing therapeutics that target the microtubular cytoskeleton structure of pathogens to prevent the spread of diseases.
Athebio AG
Schlieren · Since 2019
The core activity of Athebio AG is the development and provision of proprietary technology for the creation of targeted therapeutics with improved efficacy and safety, particularly through the use of "plug & play" DARPin technology (Athebody). The company focuses on partnering with pharmaceutical companies to develop and market innovative medicines.
Atopia Therapeutics SA
Geneva · Since 2016
Atopia Therapeutics SA is developing a disease‑modifying therapy for asthma and other allergic diseases. Its lead candidate, ATP‑R13, is a patented recombinant protein derived from a Helicobacter pylori molecule intended for oral administration to modulate immune tolerance and reduce inflammation; the company holds an exclusive worldwide licence from the University of Zurich and is conducting IND‑enabling activities.
Atreon SA
Pully · Since 2021
Atreon SA develops AI-driven digital health solutions, including digital biomarkers and mobile and web platforms for remote monitoring of musculoskeletal and chronic pain conditions. The company collaborates with academic partners on patient-centric design, algorithm development, data safety and real-world evidence generation.
Aurealis Therapeutics AG
Zug · Since 2018
The core activity of Aurealis Therapeutics is the development and marketing of bacteria-based cell and gene therapies for the treatment of chronic wounds and cancer. In particular, the company focuses on the development of proprietary technologies that use genetically modified Lactococcus cremoris bacteria to produce multiple human therapeutic proteins. The company's two leading clinical products are AUP-16 for chronic wounds and AUP-55 for cancer.
Autolus Switzerland AG
Basel · Since 2023
Autolus Switzerland AG develops advanced autologous CAR T cell therapies for patients with cancer and autoimmune diseases, applying chimeric antigen receptors, advanced cell programming and T cell manufacturing. The company advances clinical‑stage programs for hematological and solid tumor indications, including the obe‑cel candidate for B‑cell acute lymphoblastic leukemia.
Avosano Industrie Service AG
Niederbipp · Since 2004
Avosano Industrie Service AG is a specialist provider of pharmaceutical logistics and supply-chain services. It handles storage, processing and distribution of medicines and offers complementary services such as order entry, customer service, accounts receivable management, emergency deliveries, quality control and secondary packaging.
Outbound Leads by COHAGALeadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Discover LeadhubHow the search works, what each filter means, and how the results come together.
Source: Federal Statistical Office, UID register